Faculty Profile
Minh Tung Phung, PhD, MPH
- Research Investigator, Epidemiology
PhD, University of Michigan, 2022
MPH, University of Auckland, New Zealand, 2018
MPH, University of Auckland, New Zealand, 2018
Research interests:
Cancer epidemiology, women's health, population-based studies, large-scale dataset, precision health, health equity.
Dr. Phung's research interests span across the cancer continuum, including cancer etiology, prevention, and survivorship. His research has focused on establishing new population-based studies to collect primary data to study cancer risk and survivorship; analyzing large-scale datasets, such as electronic health records, consortium and administrative data, to develop models for precision medicine in cancer, and implementing these models into clinical practice; and partnering with communities to improve cancer screening and health equity in underserved populations. His research has specifically focused on women's cancers, including breast, cervical, and ovarian cancers.
Research Projects:
1. Establish a state-wide cohort study of 100,000 people aged 18-49 who live in Michigan to study the impacts of environmental exposures and cancer risk (MI-CARES, https://micares.health/)
2. Establish a state-wide cohort of young-onset breast cancer patients in Michigan to study disease risk and survivorship (YO MI-CARES, https://yomi-cares.sph.umich.edu/).
3. Establish a state-wide survivor cohort in Michigan to study ovarian cancer survivorship (MI SOCIAL, https://mi-social.sph.umich.edu/)
4. Develop and validate a risk stratification model for ovarian cancer precision prevention and explore the implementation of this model into clinical practice.
5. Develop an electronic health record (EHR)-based model for ovarian cancer early diagnosis and externally validate this model using administrative data.
6. Improve cervical cancer screening in underserved populations through HPV self-sampling, digital health, and community engagement. My research has currently focused on people in Vietnam and Vietnamese immigrants in the US, but will expand to other underserved populations.
Cancer epidemiology, women's health, population-based studies, large-scale dataset, precision health, health equity.
Dr. Phung's research interests span across the cancer continuum, including cancer etiology, prevention, and survivorship. His research has focused on establishing new population-based studies to collect primary data to study cancer risk and survivorship; analyzing large-scale datasets, such as electronic health records, consortium and administrative data, to develop models for precision medicine in cancer, and implementing these models into clinical practice; and partnering with communities to improve cancer screening and health equity in underserved populations. His research has specifically focused on women's cancers, including breast, cervical, and ovarian cancers.
Research Projects:
1. Establish a state-wide cohort study of 100,000 people aged 18-49 who live in Michigan to study the impacts of environmental exposures and cancer risk (MI-CARES, https://micares.health/)
2. Establish a state-wide cohort of young-onset breast cancer patients in Michigan to study disease risk and survivorship (YO MI-CARES, https://yomi-cares.sph.umich.edu/).
3. Establish a state-wide survivor cohort in Michigan to study ovarian cancer survivorship (MI SOCIAL, https://mi-social.sph.umich.edu/)
4. Develop and validate a risk stratification model for ovarian cancer precision prevention and explore the implementation of this model into clinical practice.
5. Develop an electronic health record (EHR)-based model for ovarian cancer early diagnosis and externally validate this model using administrative data.
6. Improve cervical cancer screening in underserved populations through HPV self-sampling, digital health, and community engagement. My research has currently focused on people in Vietnam and Vietnamese immigrants in the US, but will expand to other underserved populations.
View full list of publications at Pubmed
Phung MT, Lee AW, McLean K, Anton-Culver H, Bandera EV, Carney ME, Chang-Claude J, Cramer DW, Doherty JA, Fortner RT, Goodman MT, Harris HR, Jensen A, Modugno F, Moysich KB, Pharoah PDP, Qin B, Terry KL, Titus LJ, Webb PM; Australian Ovarian Cancer Study Group; Wu AH, Zeinomar N, Ziogas A, Berchuck A, Cho KR, Hanley GE, Meza R, Mukherjee B, Pike MC, Pearce CL*, Trabert B*; Ovarian Cancer Association Consortium. A framework for assessing interactions for risk stratification models: The example of ovarian cancer. J Natl Cancer Inst. 2023 Jul 12:djad137. doi: 10.1093/jnci/djad137. Epub ahead of print. PMID: 37436712.
Phung MT, An PL, Vinh NN, Le HHTC, McLean K, Meza R, Mukherjee B, Lee AW, Pearce CL. A comparative study on behavior, awareness and belief about cervical cancer among rural and urban women in Vietnam. PLOS Glob Public Health. 2023 Jun 6;3(6):e0001817. doi: 10.1371/journal.pgph.0001817. PMID: 37279208; PMCID: PMC10243615.
Phung MT, Pearce CL, Meza R, Jeon J. Trends of ovarian cancer incidence by histotype and race/ethnicity in the U.S.: 1992-2019. Cancer Research Communications. 3 January 2023; 3 (1): 1–8. https://doi.org/10.1158/2767-9764.CRC-22-0410
Phung MT, Muthukumar A, Trabert B, Webb PM, Jordan SJ, Terry KL, Cramer DW, Titus LJ, Risch HA, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich KB, Jensen A, Kjaer SK, Anton-Culver H, Ziogas A, Berchuck A, Khoja L, Wu AH, Pike MC, Pearce CL, Lee AW on behalf of the Ovarian Cancer Association Consortium. Effects of risk factors for ovarian cancer in women with and without endometriosis. Fertil Steril. 2022 Sep 28:S0015-0282(22)00475-7. PMID: 36182623.
Phung MT, Alimujiang A, Berchuck A, Bandera EV, Chang-Claude J, Chase A, Doherty JA, Grout B, Goodman MT, Hanley GE, Lee AW, McKinnon Deurloo C, Menon U, Modugno F, Pharoah PDP, Pike MC, Richardson J, Risch HA, Sieh W, Terry KL, Webb PM, Wentzensen N, Wu AH, Pearce CL; on behalf of the Multidisciplinary Ovarian Cancer Outcomes Group and the Ovarian Cancer Association Consortium. Reproductive factors do not influence survival with ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):909-913. PMID: 35064059.
Phung MT, Lee AW, Wu AH, Berchuck A, Cho KR, Cramer DW, Doherty JA, Goodman MT, Hanley GE, Harris HR, McLean K, Modugno F, Moysich KB, Mukherjee B, Schildkraut JM, Terry KL, Titus LJ, Jordan SJ, Webb PM, Pike MC, Pearce CL. Depot-medroxyprogesterone acetate use is associated with decreased risk of ovarian cancer: The mounting evidence of a protective role of progestins. Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):927-935. PMID: 33619020. Featured as the Editors’ Selected Article from May 2022 Issue
Phung MT, Lee AW, McLean K, Anton-Culver H, Bandera EV, Carney ME, Chang-Claude J, Cramer DW, Doherty JA, Fortner RT, Goodman MT, Harris HR, Jensen A, Modugno F, Moysich KB, Pharoah PDP, Qin B, Terry KL, Titus LJ, Webb PM; Australian Ovarian Cancer Study Group; Wu AH, Zeinomar N, Ziogas A, Berchuck A, Cho KR, Hanley GE, Meza R, Mukherjee B, Pike MC, Pearce CL*, Trabert B*; Ovarian Cancer Association Consortium. A framework for assessing interactions for risk stratification models: The example of ovarian cancer. J Natl Cancer Inst. 2023 Jul 12:djad137. doi: 10.1093/jnci/djad137. Epub ahead of print. PMID: 37436712.
Phung MT, An PL, Vinh NN, Le HHTC, McLean K, Meza R, Mukherjee B, Lee AW, Pearce CL. A comparative study on behavior, awareness and belief about cervical cancer among rural and urban women in Vietnam. PLOS Glob Public Health. 2023 Jun 6;3(6):e0001817. doi: 10.1371/journal.pgph.0001817. PMID: 37279208; PMCID: PMC10243615.
Phung MT, Pearce CL, Meza R, Jeon J. Trends of ovarian cancer incidence by histotype and race/ethnicity in the U.S.: 1992-2019. Cancer Research Communications. 3 January 2023; 3 (1): 1–8. https://doi.org/10.1158/2767-9764.CRC-22-0410
Phung MT, Muthukumar A, Trabert B, Webb PM, Jordan SJ, Terry KL, Cramer DW, Titus LJ, Risch HA, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich KB, Jensen A, Kjaer SK, Anton-Culver H, Ziogas A, Berchuck A, Khoja L, Wu AH, Pike MC, Pearce CL, Lee AW on behalf of the Ovarian Cancer Association Consortium. Effects of risk factors for ovarian cancer in women with and without endometriosis. Fertil Steril. 2022 Sep 28:S0015-0282(22)00475-7. PMID: 36182623.
Phung MT, Alimujiang A, Berchuck A, Bandera EV, Chang-Claude J, Chase A, Doherty JA, Grout B, Goodman MT, Hanley GE, Lee AW, McKinnon Deurloo C, Menon U, Modugno F, Pharoah PDP, Pike MC, Richardson J, Risch HA, Sieh W, Terry KL, Webb PM, Wentzensen N, Wu AH, Pearce CL; on behalf of the Multidisciplinary Ovarian Cancer Outcomes Group and the Ovarian Cancer Association Consortium. Reproductive factors do not influence survival with ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):909-913. PMID: 35064059.
Phung MT, Lee AW, Wu AH, Berchuck A, Cho KR, Cramer DW, Doherty JA, Goodman MT, Hanley GE, Harris HR, McLean K, Modugno F, Moysich KB, Mukherjee B, Schildkraut JM, Terry KL, Titus LJ, Jordan SJ, Webb PM, Pike MC, Pearce CL. Depot-medroxyprogesterone acetate use is associated with decreased risk of ovarian cancer: The mounting evidence of a protective role of progestins. Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):927-935. PMID: 33619020. Featured as the Editors’ Selected Article from May 2022 Issue
Email: phungmt@umich.edu
Address: 3642 SPH I
1415 Washington Heights
Ann Arbor, MI 48109
For media inquiries: sph.media@umich.edu
Address: 3642 SPH I
1415 Washington Heights
Ann Arbor, MI 48109
For media inquiries: sph.media@umich.edu
Areas of Expertise: Cancer, Global Public Health, Health Equity, Precision Health, Women’s Health